scholarly journals Non-Coding RNAs: Novel Players in Insulin Resistance and Related Diseases

2021 ◽  
Vol 22 (14) ◽  
pp. 7716
Author(s):  
Caterina Formichi ◽  
Laura Nigi ◽  
Giuseppina Emanuela Grieco ◽  
Carla Maccora ◽  
Daniela Fignani ◽  
...  
Keyword(s):  
Insulin Resistance ◽  
Metabolic Diseases ◽  
Gene Expression Regulation ◽  
Biological Fluids ◽  
Current Evidence ◽  
Alcoholic Fatty Liver ◽  
Non Coding Rnas ◽  
Alcoholic Fatty Liver Disease

The rising prevalence of metabolic diseases related to insulin resistance (IR) have stressed the urgent need of accurate and applicable tools for early diagnosis and treatment. In the last decade, non-coding RNAs (ncRNAs) have gained growing interest because of their potential role in IR modulation. NcRNAs are variable-length transcripts which are not translated into proteins but are involved in gene expression regulation. Thanks to their stability and easy detection in biological fluids, ncRNAs have been investigated as promising diagnostic and therapeutic markers in metabolic diseases, such as type 2 diabetes mellitus (T2D), obesity and non-alcoholic fatty liver disease (NAFLD). Here we review the emerging role of ncRNAs in the development of IR and related diseases such as obesity, T2D and NAFLD, and summarize current evidence concerning their potential clinical application.

scholarly journals Disease, Drugs and Dysbiosis: Understanding Microbial Signatures in Metabolic Disease and Medical Interventions

2020 ◽  
Vol 8 (9) ◽  
pp. 1381
Author(s):  
Ceri Proffitt ◽  
Gholamreza Bidkhori ◽  
David Moyes ◽  
Saeed Shoaie
Keyword(s):  
Metabolic Disease ◽  
Potential Role ◽  
Metabolic Diseases ◽  
Alcoholic Fatty Liver ◽  
Medical Interventions ◽  
Microbial Dysbiosis ◽  
Health And Disease ◽  
Alcoholic Fatty Liver Disease

Since the discovery of the potential role for the gut microbiota in health and disease, many studies have gone on to report its impact in various pathologies. These studies have fuelled interest in the microbiome as a potential new target for treating disease Here, we reviewed the key metabolic diseases, obesity, type 2 diabetes and atherosclerosis and the role of the microbiome in their pathogenesis. In particular, we will discuss disease associated microbial dysbiosis; the shift in the microbiome caused by medical interventions and the altered metabolite levels between diseases and interventions. The microbial dysbiosis seen was compared between diseases including Crohn’s disease and ulcerative colitis, non-alcoholic fatty liver disease, liver cirrhosis and neurodegenerative diseases, Alzheimer’s and Parkinson’s. This review highlights the commonalities and differences in dysbiosis of the gut between diseases, along with metabolite levels in metabolic disease vs. the levels reported after an intervention. We identify the need for further analysis using systems biology approaches and discuss the potential need for treatments to consider their impact on the microbiome.

scholarly journals Role of hepatokines in non-alcoholic fatty liver disease

2019 ◽  
Vol 7 (4) ◽  
pp. 143-148 ◽  
Author(s):  
Yini Ke ◽  
Chengfu Xu ◽  
Jin Lin ◽  
Youming Li
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Metabolic Diseases ◽  
Alcoholic Fatty Liver ◽  
Diabetes And Obesity ◽  
Alcoholic Fatty Liver Disease ◽  
Muscular Tissues

Abstract Non-alcoholic fatty liver disease (NAFLD) is closely associated with metabolic diseases like type 2 diabetes and obesity. In recent decades, accumulating evidence has revealed that the hepatokines, proteins mainly secreted by the liver, play important roles in the development of NAFLD by acting directly on the lipid and glucose metabolism. As a member of organokines, the hepatokines establish the communication between the liver and the adipose, muscular tissues. In this review, we summarize the current understanding of the hepatokines and how they modulate the pathogenesis of metabolic disorders especially NAFLD.

scholarly journals Non-Alcoholic Steatohepatitis (NASH) and Organokines: What Is Now and What Will Be in the Future

2022 ◽  
Vol 23 (1) ◽  
pp. 498
Author(s):  
João Paulo Margiotti dos Santos ◽  
Mariana Canevari de Maio ◽  
Monike Alves Lemes ◽  
Lucas Fornari Laurindo ◽  
Jesselina Francisco dos Santos Haber ◽  
...  
Keyword(s):  
Oxidative Stress ◽  
Insulin Resistance ◽  
Fatty Liver Disease ◽  
Alcoholic Fatty Liver ◽  
Alcoholic Steatohepatitis ◽  
Endocrine Organs ◽  
Alcoholic Fatty Liver Disease ◽  
Lobular Inflammation

Non-alcoholic steatohepatitis (NASH) is characterized by steatosis, lobular inflammation, and enlargement of the diameter of hepatocytes (ballooning hepatocytes), with or without fibrosis. It affects 20% of patients with non-alcoholic fatty liver disease (NAFLD). Due to liver dysfunction and the numerous metabolic changes that commonly accompany the condition (obesity, insulin resistance, type 2 diabetes, and metabolic syndrome), the secretion of organokines is modified, which may contribute to the pathogenesis or progression of the disease. In this sense, this study aimed to perform a review of the role of organokines in NASH. Thus, by combining descriptors such as NASH, organokines, oxidative stress, inflammation, insulin resistance, and dyslipidemia, a search was carried out in the EMBASE, MEDLINE-PubMed, and Cochrane databases of articles published in the last ten years. Insulin resistance, inflammation and mitochondrial dysfunction, fructose, and intestinal microbiota were factors identified as participating in the genesis and progression of NASH. Changes in the pattern of organokines secretion (adipokines, myokines, hepatokines, and osteokines) directly or indirectly contribute to aggravating the condition or compromise homeostasis. Thus, further studies involving skeletal muscle, adipose, bone, and liver tissue as endocrine organs are essential to better understand the modulation of organokines involved in the pathogenesis of NASH to advance in the treatment of this disease.

scholarly journals Non-alcoholic fatty liver disease and metabolic syndrome in childhood

2020 ◽  
Vol 183 (11) ◽  
pp. 51-61
Author(s):  
N. N. Vlasov ◽  
E. A. Kornienko
Keyword(s):  
Metabolic Syndrome ◽  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Lifestyle Changes ◽  
Alcoholic Fatty Liver ◽  
Ample Evidence ◽  
Alcoholic Fatty Liver Disease

There is ample evidence that insulin resistance, hyperinsulinemia, and obesity are at the heart of the development of non-alcoholic fatty liver disease (NAFLD). The disease is now considered as the hepatic component of metabolic syndrome (MS).64 children with NAFLD were assessed for metabolic syndrome stigma. An analysis was also made on the state of the problem according to the literature on the general links of the pathogenesis of these conditions, methods of diagnosis and treatment of NAFLD.All components of MS are observed with different frequencies in patients with NAFD. This disease, together with type 2 diabetes mellitus, becomes very common diseases in childhood. The incidence of NAFLD in children is constantly growing, it has begun to occur in infants, an outcome in cirrhosis of the liver is possible within childhood, although the prognosis for NAFLD remains definitely uncertain. Weight loss with a low glycemic index diet, regular exercise, and other lifestyle changes are the mainstay of NAFLD treatment, but not yet very effective for various reasons. In these conditions, it is necessary to increase the role of primary prevention of MS and NAFLD.

Endoscopic Duodenal Mucosal Resurfacing for the Treatment of Type 2 Diabetes

2018 ◽  
Vol 36 (4) ◽  
pp. 322-324 ◽  
Author(s):  
Alia Hadefi ◽  
Vincent Huberty ◽  
Arnaud Lemmers ◽  
Marianna Arvanitakis ◽  
David Maggs ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Bypass Surgery ◽  
Metabolic Diseases ◽  
Invasive Procedure ◽  
Diabetic Patients ◽  
Intestinal Bypass ◽  
Alcoholic Fatty Liver ◽  
Glucose Homoeostasis ◽  
Alcoholic Fatty Liver Disease

Type 2 diabetes is a pandemic disease with an incidence that has risen steadily over recent decades. Experimental evidence in animals has demonstrated that intestinal bypass surgery of the upper small intestine, particularly the duodenum, has an important role in glucose homoeostasis. Furthermore, Roux-en-Y bypass performed as bariatric surgery has shown to correct hyperglycaemia from the first postoperative days in obese diabetic patients. Therefore, on the basis of these considerations, duodenal mucosal resurfacing was studied in type 2 diabetes patients as a minimally invasive procedure that could offer an alternative treatment for these patients. Further studies, and particularly large controlled trials, are needed to determine the place of this procedure in the treatment of type 2 diabetes as well as other metabolic diseases such as non-alcoholic fatty liver disease/non-alcoholic steatohepatitis.

scholarly journals Microbiota, type 2 diabetes and non-alcoholic fatty liver disease: protocol of an observational study

2019 ◽  
Vol 17 (1) ◽  
Author(s):  
Benedetta M. Motta ◽  
Christoph Grander ◽  
Martin Gögele ◽  
Luisa Foco ◽  
Vladimir Vukovic ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Liver Disease ◽  
Fatty Liver Disease ◽  
Liver Stiffness ◽  
Alcoholic Fatty Liver ◽  
Study Participants ◽  
The Relationship ◽  
Alcoholic Fatty Liver Disease

Abstract Background Non-alcoholic fatty liver disease (NAFLD) is characterized by triglyceride accumulation in the hepatocytes in the absence of alcohol overconsumption, commonly associated with insulin resistance and obesity. Both NAFLD and type 2 diabetes (T2D) are characterized by an altered microbiota composition, however the role of the microbiota in NAFLD and T2D is not well understood. To assess the relationship between alteration in the microbiota and NAFLD while dissecting the role of T2D, we established a nested study on T2D and non-T2D individuals within the Cooperative Health Research In South Tyrol (CHRIS) study, called the CHRIS-NAFLD study. Here, we present the study protocol along with baseline and follow-up characteristics of study participants. Methods Among the first 4979 CHRIS study participants, 227 individuals with T2D were identified and recalled, along with 227 age- and sex-matched non-T2D individuals. Participants underwent ultrasound and transient elastography examination to evaluate the presence of hepatic steatosis and liver stiffness. Additionally, sampling of saliva and faeces, biochemical measurements and clinical interviews were carried out. Results We recruited 173 T2D and 183 non-T2D participants (78% overall response rate). Hepatic steatosis was more common in T2D (63.7%) than non-T2D (36.3%) participants. T2D participants also had higher levels of liver stiffness (median 4.8 kPa, interquartile range (IQR) 3.7, 5.9) than non-T2D participants (median 3.9 kPa, IQR 3.3, 5.1). The non-invasive scoring systems like the NAFLD fibrosis score (NFS) suggests an increased liver fibrosis in T2D (mean − 0.55, standard deviation, SD, 1.30) than non-T2D participants (mean − 1.30, SD, 1.17). Discussion Given the comprehensive biochemical and clinical characterization of study participants, once the bioinformatics classification of the microbiota will be completed, the CHRIS-NAFLD study will become a useful resource to further our understanding of the relationship between microbiota, T2D and NAFLD.

Non-alcoholic fatty liver disease: the role of the nurse

2020 ◽  
Vol 18 (Sup6) ◽  
pp. S15-S21
Author(s):  
Lea Ladegaard Grønkjær ◽  
Charlotte Wernberg ◽  
Mette Munk Lauridsen
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Western World ◽  
Alcoholic Fatty Liver ◽  
Obesity Epidemic ◽  
Adults And Children ◽  
Alcoholic Fatty Liver Disease

Obesity is a frequent cause of morbidity in the Western world, and its prevalence has doubled since 1980. It is well known that conditions such as cardiovascular disease and type 2 diabetes can be serious consequences of obesity. However, less is known about whether the liver may also be affected by the obesity epidemic. Non-alcoholic fatty liver disease (NAFLD) is present in more than a quarter of the adult Western population, and the prevalence is increasing among both adults and children. NAFLD thus represents a common liver disease in the Western world. This is worrisome, because NAFLD can cause liver inflammation and various stages of fibrosis and eventually result in cirrhosis and hepatocellular carcinoma, which both have a high mortality rate due to related complications. Lifestyle change is the most important aspect in the prevention and treatment of NAFLD, and nurses play an important role in the early detection of NAFLD and the prevention of its possible progression.

Blood triacylglycerols: a lipidomic window on diet and disease

2016 ◽  
Vol 44 (2) ◽  
pp. 638-644 ◽  
Author(s):  
Francis Sanders ◽  
Ben McNally ◽  
Julian L. Griffin
Keyword(s):  
Fatty Liver Disease ◽  
Metabolic Diseases ◽  
Clinical Chemistry ◽  
Total Concentration ◽  
Direct Infusion ◽  
Alcoholic Fatty Liver ◽  
Tissue Extracts ◽  
The Individual ◽  
Alcoholic Fatty Liver Disease

Although the measurement of triacylglycerols (TAGs) by clinical chemistry has been used in the diagnosis of a range of metabolic diseases, such approaches ignore the different species of TAGs that contribute to the total concentration. With the advent of LC and direct infusion forms of MS it is now possible to profile the individual TAGs in blood plasma or tissue extracts. This mini review surveys the information that is obtainable from the lipidomic profiling of TAGs in following metabolic diseases such as type 2 diabetes (T2DM), cardiovascular disease (CVD) and non-alcoholic fatty liver disease, as well as the development of insulin resistance and obesity.

Sign in / Sign up

Export Citation Format

Share Document